Glancy
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of GTx,
Inc. (“GTx” of the “Company”) (NASDAQ:GTXI) concerning possible
violations of federal securities laws. The investigation focuses on
certain statements issued by GTx concerning the Company’s operations and
financial prospects.
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at shareholders@glancylaw.com
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
GTx is a biopharmaceutical company engaged in the discovery, development
and commercialization of small molecules for the treatment of cancer,
cancer supportive care and other serious medical conditions. Its lead
product candidate, enobosarm, is a Phase III investigational drug for
the prevention and treatment of muscle wasting in patients with advanced
non-small cell lung cancer. The investigation is related to the
Company’s August 19, 2013, announcement that enobosarm fell short of key
goals agreed upon with the U.S. Food and Drug Administration in two
Phase III clinical trials in terms of increasing lean body mass and
improving physical function. Following this news, the price of GTx
shares dropped more than 60% from the previous day’s closing price, to
close at $1.43 per share, on volume of more than 17 million shares
traded.
If you purchased GTx shares, if you have information or would like to learn
more about these claims or if you have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century
Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888)
773-9224, or contact Gregory
Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by
e-mail to shareholders@glancylaw.com,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2013